Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 10, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

May 18, 2023

Conditions
Chronic Kidney Disease Stage 3BChronic Kidney Disease stage4Diabetes Mellitus, Type 2
Interventions
OTHER

Sulforaphane, administered as Broccoli sprout extract

Patients will randomized to BSE or Control Group. The group BSE will receive the sulforaphane, administered as broccoli sprout extract for 12 weeks. The dose will increase every four weeks if no side-effects are reported (50 µmmol/day; 100 µmmol/day and 150 µmmol/day, respectivelly). The Control group will receive a placebo (maltodextrin sprayed with copper-chlorophyllin) for the same period (12 weeks). The BSE/placebo will be administered as powder provided in 10 ml of water in the morning in a double-blind manner as dry mixtures in sealed portion size bags of similar shape and size.

Trial Locations (12)

14134

Karolinska Institutet, Stockholm

18288

Danderyds sjukhus AB, Stockholm

20502

Skånes universitetssjukhus, Malmo

22185

Skånes University Hospital Sus, Lund

41345

Sahlgrenska Universitetssjukhuset, Gothenburg

43281

Hallands Hospital Varberg, Varberg

58183

Linköpings universitet, Linköping

59333

Västervikssjukhus, Västervik

72189

Västmanlands Hospital Västerås, Västerås

75185

Akademiska sjukhuset, Uppsala

80187

Gävle Hospital, Gävle

90185

Norrlands Universitetssjukhus, Umeå

All Listed Sponsors
collaborator

Lantmännen

UNKNOWN

lead

Karolinska Institutet

OTHER

NCT04858854 - Effect of Broccoli Sprout Extract in Patients With Chronic Kidney Disease With Diabetes Type 2 | Biotech Hunter | Biotech Hunter